porcin
reproduct
respiratori
syndrom
prr
chronic
viral
diseas
pig
pose
huge
econom
concern
pig
industri
worldwid
studi
develop
biodegrad
plga
poli
llactidecoglycolid
nanoparticleentrap
kill
prrsv
vaccin
nanokag
administ
intranas
pig
evalu
immun
correl
nanokag
vaccin
homolog
viru
challeng
pig
complet
clearanc
viremia
observ
week
associ
signific
increas
viru
neutral
titer
lung
compar
unvaccin
kill
vaccin
vaccin
pig
lung
homogen
sera
nanokag
vaccin
pig
higher
level
ifng
lower
level
tgfb
control
group
restimul
mononuclear
cell
isol
lung
blood
bal
tbln
nanokag
vaccin
pig
secret
significantli
increas
level
cytokin
ifng
addit
higher
frequenc
gd
cell
reduc
frequenc
tregulatori
cell
observ
nanokag
vaccin
pig
thu
intranas
deliveri
nanokag
vaccin
may
suitabl
strategi
elicit
antiprrsv
immun
respons
requir
better
clear
viremia
pig
crown
porcin
reproduct
respiratori
syndrom
prr
first
report
us
keffab
prr
endem
porkproduc
countri
respons
major
econom
loss
swine
industri
estim
annual
loss
million
us
economi
holtkamp
kliebenstein
clinic
sign
prr
pig
includ
fever
anorexia
respiratori
diseas
poor
reproduct
perform
pregnant
pig
character
abort
mummifi
fetu
weakborn
piglet
done
et
al
causal
agent
prr
viru
prrsv
envelop
posit
sens
singlestrand
rna
viru
belong
famili
arterivirida
king
et
al
prrsv
modul
pig
immun
system
earli
twoday
continu
sever
week
postinfect
dwivedi
et
al
mateu
diaz
prrsv
infect
pig
product
import
cytokin
ifng
delay
reduc
amount
immun
modul
caus
prrsv
attribut
virusmedi
suppress
host
ifna
product
albina
et
al
addit
viru
help
induct
veterinari
microbiolog
secret
interleukin
il
transform
growth
factorb
tgfb
upregul
tregulatori
cell
treg
silvacampa
et
al
viru
neutral
vn
antibodi
import
viral
clearanc
role
vn
antibodi
clear
prrsv
infect
pig
unclear
diaz
et
al
howev
passiv
transfer
vn
antibodi
shown
provid
protect
prrsv
challeng
osorio
et
al
control
prr
outbreak
modifi
live
prrsv
vaccin
prrsmlv
wide
use
confer
protect
homolog
viru
incomplet
protect
reinfect
heterolog
virus
mengel
et
al
limit
prrsmlv
report
appear
revert
vaccin
viru
certain
pig
li
et
al
mengel
et
al
nielsen
et
al
avail
kill
vaccin
safe
efficaci
poor
bassaganyariera
et
al
charerntantanakul
pira
et
al
stimul
immun
system
system
result
mainli
system
protect
low
mucos
immun
respons
contrast
optimum
stimul
mucos
immun
system
provid
mucos
system
immun
result
inhibit
entri
pathogen
bodi
holmgren
et
al
nanotechnolog
base
vaccin
deliveri
system
innov
centuri
panyam
labhasetwar
nanoparticl
offer
advantag
increas
effici
drug
vaccin
deliveri
also
possess
adjuv
properti
gupta
et
al
poli
llactidecoglycolid
plga
nanoparticlemedi
deliveri
vaccin
shown
effect
elicit
protect
immun
respons
administ
either
mucos
system
rout
eldridg
et
al
spier
et
al
plga
biocompat
biodegrad
protect
entrap
vaccin
proteas
mediat
degrad
mucos
surfac
fda
approv
agent
lu
et
al
plga
help
sustain
releas
entrap
vaccin
thu
limit
need
booster
dose
thomasin
et
al
therefor
goal
studi
develop
plga
nanoparticleencapsul
prrsv
kill
vaccin
investig
efficaci
pig
vaccin
intranas
rout
result
suggest
strategi
potenti
gener
antiprrsv
immun
respons
better
clearanc
viremia
stabl
mycoplasmafre
cell
african
green
monkey
kidney
cell
line
support
growth
prrsv
kim
et
al
use
prepar
prrsv
stock
kill
viral
antigen
immunolog
assay
cell
maintain
dulbecco
minimum
essenti
medium
dmem
lonza
supplement
fetal
bovin
serum
atlanta
biolog
co
viru
infect
dmem
supplement
hors
serum
use
prepar
nanoparticl
plga
poli
llactidecoglycolid
mw
polyvinyl
alcohol
mw
sigmaaldrich
dicholoro
methan
acro
organ
bca
bicinchonin
acid
protein
assay
kit
pierc
use
convent
larg
whiteduroc
crossbr
wean
specificpathogenfre
pig
week
age
receiv
hous
facil
swine
herd
sourc
piglet
confirm
seroneg
prrsv
porcin
respiratori
coronaviru
transmiss
gastroenter
viru
porcin
circoviru
blood
sampl
collect
piglet
confirm
neg
prrsv
antibodi
pig
allow
acclim
week
initi
experi
throughout
durat
studi
anim
receiv
food
water
ad
libitum
cellmonolay
confluent
infect
north
american
prototyp
prrsv
strain
kim
et
al
provid
dr
eric
nelson
south
dakota
state
univers
attenu
passag
sever
time
vitro
use
multipl
infect
roller
bottl
tissu
cultur
flask
freezethaw
three
time
cell
show
cytopath
effect
harvest
infect
cell
cultur
fluid
clarifi
remov
cell
debri
g
min
subject
toultracentrifug
witha
sucros
overlay
g
h
pool
semipurifi
prrsv
antigen
suspend
steril
pb
titrat
determin
viral
titer
prrsv
inactiv
use
nm
uvirradi
el
seri
uv
lamp
uvp
llc
ca
h
inactiv
confirm
cell
cultur
indirect
immunofluoresc
assay
cell
semipurifi
viru
sonic
probe
sonic
amplitud
cycl
protein
content
estim
use
bca
assay
kit
pierc
aliquot
store
control
antigen
prepar
manner
use
uninfect
cell
nanoparticl
prepar
standard
doubl
emuls
solvent
evapor
techniqu
cao
schoichet
briefli
plga
mg
dissolv
ml
dichloromethan
ml
kill
protein
mg
ad
mixtur
homogen
use
brinkman
polytron
homogen
rpm
homogen
mixtur
ad
ml
aqueou
solut
polyvinyl
alcohol
pva
homogen
min
final
prepar
stir
overnight
room
temperatur
rt
allow
solvent
evapor
nanoparticl
wash
distil
water
three
time
centrifug
rpm
min
final
wash
nanoparticl
freezedri
store
use
immun
size
morpholog
nanoparticl
determin
scan
electron
microscopi
hitachi
n
briefli
freezedri
nanoparticl
mount
adhes
stub
coat
goldpalladium
vacuum
use
ion
coater
coat
specimen
examin
microscop
kv
amount
entrap
prrsv
antigen
nanoparticl
determin
describ
previous
rajapaksa
et
al
briefli
freezedri
nanoparticl
mg
dissolv
ml
n
sodium
hydroxid
incub
h
constant
stir
mixtur
vortex
centrifug
rpm
min
supernat
collect
analyz
protein
content
help
seri
bsa
standard
prepar
n
naoh
use
bca
protein
assay
kit
pierc
usa
pig
n
divid
four
group
n
pig
per
group
group
mock
pig
group
ii
inocul
normal
salin
group
iii
inocul
kill
antigen
kag
group
iv
inocul
nanoparticleentrap
kill
antigen
nanokag
amount
prrsv
antigen
dose
nanokag
kag
one
mg
equival
approxim
tcid
inactiv
viru
inocul
includ
challeng
viru
tcid
ml
per
pig
administ
intranas
group
ii
iii
iv
challeng
day
postimmun
dpi
euthan
day
postchalleng
dpc
pc
mockinocul
pig
euthan
separ
prior
kill
infect
anim
pig
hous
maintain
larg
anim
facil
clinic
sampl
pig
collect
anim
euthan
per
protocol
approv
institut
anim
care
use
committe
biolog
agent
handl
per
institut
biosafeti
committe
ohio
state
univers
ohio
evalu
viremia
titrat
prrsv
specif
vn
antibodi
ml
blood
sampl
collect
dpi
dpc
serum
separ
clot
blood
aliquot
store
other
found
suitabl
lung
homogen
lysat
instead
bal
fluid
cytokin
viru
evalu
pig
lung
barb
et
al
renukaradhya
et
al
briefli
g
lung
tissu
sampl
collect
dmem
minc
blend
min
laboratori
blender
seward
clarifi
supernat
gml
aliquot
store
isol
pbmc
blood
collect
acid
citrat
dextros
solut
euthan
pig
lung
mononuclear
cell
lung
mnclmnc
individu
pig
isol
describ
dwivedi
et
al
airway
lavag
collect
bal
fluid
use
steril
ice
cold
pb
contain
edta
dwivedi
et
al
sampl
tracheobronchi
lymph
node
tbln
collect
dmem
mnc
isol
describ
dwivedi
et
al
prrsv
titer
serum
vn
antibodi
titer
serum
lung
homogen
analyz
indirect
immunofluoresc
assay
ifa
christopherhen
et
al
briefli
viru
titrat
confluent
monolay
cell
microtit
plate
treat
dilut
serum
h
vnt
serum
lung
homogen
heat
inactiv
min
twofold
dilut
incub
equal
volum
prrsv
tcid
per
well
h
suspens
transfer
microtit
plate
contain
confluent
monolay
cell
incub
h
follow
treatment
antipprsv
nucleocapsid
protein
specif
mab
conjug
antimous
igg
h
l
secondari
antibodi
mount
glycerolpb
ratio
viru
induc
cytopath
effect
examin
fluoresc
microscop
vnt
reciproc
dilut
greater
reduct
fluoresc
foci
compar
viru
control
tcid
consid
titer
presenc
prrsv
specif
iga
antibodi
lung
homogen
analyz
elisa
describ
dwivedi
et
al
briefli
elisa
plate
coat
pretitr
semipurifi
prrsv
antigen
mgml
recombin
prrsv
nucleocapsid
n
protein
mgml
baker
et
al
johnson
et
al
kind
gift
dr
murtaugh
univers
minnesota
carbonatebicarbon
buffer
ph
overnight
plate
wash
treat
block
buffer
bsa
tween
pb
h
rt
serum
lung
homogen
sampl
dilut
ad
incub
h
rt
bound
viru
specif
isotyp
antibodi
detect
use
affin
purifi
ensur
class
specif
goat
antipig
iga
secondari
antibodi
conjug
hrp
cat
bethyl
laboratori
inc
final
plate
develop
use
chromogen
tmb
tetramethylbenzidin
kpl
reaction
stop
use
phosphor
acid
plate
read
nm
elimin
background
activ
also
includ
nonprrsv
specif
antigen
coat
control
plate
block
treat
exactli
test
sampl
sidebysid
od
valu
obtain
control
plate
subtract
experiment
plate
obtain
correct
absorb
valu
lung
homogen
mean
od
valu
prrsv
neg
pig
lung
homogen
sampl
plu
standard
deviat
consid
positiveneg
cutoff
five
million
pig
pbmc
tbln
mnc
lung
mnc
restimul
ex
vivo
tissu
cultur
plate
absenc
presenc
kill
semipurifi
ag
mgml
enrich
rpmi
h
harvest
cultur
supernat
analyz
cytokin
elisa
amount
cytokin
secret
cell
cultur
absenc
ag
subtract
respect
restimul
experiment
well
valu
serum
sampl
cultur
supernat
lung
homogen
analyz
ifng
proinflammatori
immunosuppress
tgfb
cytokin
elisa
renukaradhya
et
al
briefli
elisa
plate
coat
cytokin
specif
captur
antibodi
carbonatebicarbon
buffer
ph
block
block
buffer
test
sampl
cytokin
standard
ad
incub
overnight
wash
respect
cytokin
specif
detect
antibodi
ad
incub
h
rt
plate
wash
treat
hrpconjug
streptavidin
biosourc
incub
h
rt
wash
plate
develop
ad
tmb
kpl
reaction
stop
use
phosphor
acid
plate
read
microtit
plate
reader
od
nm
within
min
cytokin
level
determin
comparison
standard
curv
gener
od
valu
known
concentr
swine
recombin
cytokin
amount
cytokin
present
lung
homogen
convert
pg
per
gm
lung
tissu
flow
cytometri
analysi
perform
determin
phenotyp
frequenc
differ
immun
cell
multicolor
immunoassay
describ
dwivedi
et
al
manickam
et
al
briefli
singl
cell
suspens
pbmc
lmnc
bal
tbln
iln
resuspend
fluorescenceactiv
cell
sort
fac
buffer
plate
ubottom
plate
treat
pig
serum
block
fc
receptor
cell
treat
fluorochrom
tag
purifi
biotin
label
pig
specif
mab
southern
biotech
bd
bioscienc
vmrd
slaii
serotech
ebiosci
respect
isotyp
control
mab
cell
wash
treat
streptavidinconjug
fluorochrom
respect
antispeci
isotyp
specif
secondari
antibodi
conjug
fluorochrom
final
cell
fix
wash
fac
buffer
intracellular
stain
cell
stain
first
cell
surfac
treat
permeabil
buffer
pb
contain
saponin
formaldehyd
stain
fluorochromeconjug
pig
crossreact
antirat
mab
immunostain
cell
acquir
use
fac
aria
ii
bd
bioscienc
flow
cytomet
analysi
done
determin
differ
immun
cell
popul
base
phenotyp
thelper
cell
cell
thelpermemori
cell
gd
cell
tregulatori
cell
myeloid
cell
c
slaii
dendrit
cell
rich
fraction
analyz
use
flowjo
softwar
tree
star
inc
usa
frequenc
individu
immun
cell
analyz
total
event
data
express
mean
ae
sem
three
pig
statist
analys
perform
use
one
way
analysi
varianc
anova
follow
tukey
hsd
posttest
use
graphpad
instat
softwar
version
window
establish
differ
differ
experiment
group
statist
signific
assess
p
alphabet
b
c
figur
repres
statist
signific
differ
unvaccin
vs
kag
bunvaccin
vs
nanokag
c
kag
vs
nanokag
pig
nanoparticl
use
studi
character
size
morpholog
yield
protein
encapsul
effici
size
sham
well
prrsv
antigen
entrap
nanoparticl
rang
nm
fig
yield
prepar
nanoparticl
calcul
consid
amount
viral
antigen
use
ae
surfac
morpholog
nanokg
spheric
surfac
discontinu
per
sem
pictur
fig
entrap
effici
prrsv
antigen
nanokg
calcul
base
amount
total
prrsv
protein
use
entrap
immunofluoresc
assay
perform
determin
prrsv
titer
tcid
serum
sampl
collect
pc
nanokag
vaccin
pig
reduc
viremia
greater
log
pc
complet
viral
clearanc
pc
observ
fig
kag
vaccin
pig
margin
reduct
viremia
compar
unvaccin
viru
challeng
pig
fig
nanokag
vaccin
pig
increas
level
vn
titer
serum
significantli
higher
level
pc
compar
kag
vaccin
unvaccin
pig
fig
vn
titer
serum
increas
rather
decreas
pc
fig
howev
lung
homogen
nanokag
receiv
pig
significantli
increas
vn
titer
compar
unvaccin
kag
group
observ
fig
interestingli
kag
nanokag
vaccin
pig
show
significantli
increas
prrsv
specif
iga
level
lung
compar
unvaccin
viru
challeng
anim
fig
sinc
prrsv
ag
use
vaccin
prepar
elisa
semipurifi
prrsv
contain
high
level
cell
compon
therefor
want
analyz
prrsv
specif
respons
lung
homogen
pig
use
studi
use
recombin
prrsv
n
protein
iga
elisa
result
suggest
viru
specif
respons
elicit
kag
nanokag
vaccin
pig
fig
cytokin
ifng
serum
unvaccin
pig
undetect
secret
lower
level
kag
receiv
viru
challeng
pig
nanokag
vaccin
pig
significantli
increas
ifng
respons
detect
pc
fig
similarli
nanokag
enhanc
iga
neutral
antibodi
titer
serum
lung
nanokag
vaccin
viru
challeng
pig
analysi
perform
determin
prrsv
neutral
antibodi
respons
serum
b
lung
homogen
immunofluoresc
assay
c
prrsv
iga
respons
lung
homogen
prrsv
total
ag
prrsv
iga
respons
lung
homogen
prrsv
n
protein
elisa
bar
graph
repres
geometr
mean
vn
titer
log
valu
optic
densiti
valu
three
pig
ae
sem
alphabet
b
c
repres
statist
signific
differ
p
unvaccin
vs
kag
unvaccin
vs
nanokag
kag
vs
nanokag
pig
respect
immun
pig
lung
homogen
significantli
higher
level
ifng
compar
control
group
pig
pc
fig
kag
vaccin
pig
significantli
increas
tgfb
level
serum
compar
experiment
group
pc
unvaccin
viru
challeng
pig
also
increas
trend
serum
tgfb
level
pc
pc
fig
howev
nanokag
vaccin
pig
significantli
reduc
tgfb
level
serum
pc
fig
proinflammatori
cytokin
lung
homogen
significantli
reduc
nanokag
immun
kag
immun
compar
unvaccin
pig
moreov
reduct
nanokag
inocul
pig
significantli
lower
kag
immun
pig
fig
immunosuppress
cytokin
tgfb
cytokin
lung
homogen
nanokag
kag
immun
pig
significantli
reduc
compar
unvaccin
pig
pc
fig
mononuclear
cell
isol
lung
lymph
node
blood
restimul
presenc
semipurifi
kill
antigen
assess
recal
cytokin
respons
cultur
supernat
pbmc
bal
tbln
nanokag
immun
pig
significantli
increas
cytokin
ifng
compar
kag
unvaccin
viru
challeng
pig
observ
fig
fh
lmnc
nanokag
immun
pig
secret
significantli
higher
cytokin
comparison
unvaccin
kag
vaccin
pig
fig
e
secret
proinflammatori
cytokin
lmnc
bal
nanokag
immun
pig
significantli
reduc
compar
unvaccin
kag
immun
pig
fig
j
nanokag
immun
pig
secret
significantli
less
tgfb
lmnc
cultur
compar
kag
immun
group
fig
bal
compar
unvaccin
pig
fig
detect
product
lmnc
recal
respons
level
significantli
differ
data
shown
flow
cytometr
analysi
perform
day
euthanasia
pc
frequenc
total
lymphocyt
popul
significantli
increas
balmnc
nanokag
kag
immun
compar
unvaccin
pig
fig
lmnc
nanokag
immun
pig
significantli
higher
frequenc
doubl
posit
cell
compar
unvaccin
viru
challeng
pig
detect
fig
balmnc
nanokag
receiv
pig
similar
signific
increas
lymphocyt
subset
observ
fig
g
addit
increas
cell
significantli
higher
control
pig
group
fig
nanokag
kag
receiv
pig
gd
cell
frequenc
lmnc
pbmc
bal
tblnmnc
significantli
higher
compar
unvaccin
pig
fig
addit
gd
cell
popul
lmnc
balmnc
nanokag
pig
significantli
higher
kag
vaccin
group
fig
c
myeloid
cell
nanokag
pig
increas
significantli
lmnc
compar
unvaccin
viru
challeng
group
fig
pbmc
compar
kag
immun
pig
fig
dc
rich
fraction
pbmc
lmnc
nanokag
vaccin
pig
significantli
higher
unvaccin
kag
vaccin
viru
challeng
pig
fig
j
howev
find
signific
chang
myeloid
cell
dc
rich
fraction
bal
tbln
mnc
test
pig
fig
h
k
bar
data
point
graph
repres
geometr
mean
cytokin
amount
three
pig
ae
sem
alphabet
b
c
repres
statist
signific
differ
p
unvaccin
vs
kag
unvaccin
vs
nanokag
kag
vs
nanokag
pig
respect
frequenc
treg
lmnc
significantli
reduc
nanokag
immun
compar
unvaccin
pig
fig
pig
immun
kag
significantli
higher
treg
popul
lmnc
unvaccin
pig
observ
fig
treg
frequenc
pbmc
significantli
reduc
nanokag
vaccin
significantli
increas
kag
vaccin
compar
unvaccin
pig
fig
addit
tbln
nanokag
vaccin
pig
significantli
higher
popul
treg
compar
kag
receiv
pig
fig
far
research
made
sever
effort
develop
protect
kill
prrsv
vaccin
limit
success
charerntantanakul
possibl
reason
includ
inabl
deliv
kill
prrsv
vaccin
pig
immun
system
ii
like
live
prrsv
kill
viru
may
also
immunosuppress
iii
antigen
mass
use
kill
vaccin
may
insuffici
induc
protect
immun
iv
administ
kill
prrsv
vaccin
fail
elicit
adequ
cellmedi
immun
respons
suggest
need
potent
adjuv
andor
novel
deliveri
system
improv
efficaci
kill
prrsv
vaccin
clinic
challeng
pig
diseas
symptom
absent
use
strain
passag
sever
time
vitro
lack
obviou
clinic
diseas
may
due
attenu
macroscop
typic
prr
lung
lesion
distinct
therefor
paper
make
compar
lung
lesion
analys
report
comprehens
immunolog
data
relat
viremia
prrsv
neutral
antibodi
protect
pig
viremia
viru
replic
lung
transplacent
spread
viru
lopez
et
al
lopez
osorio
commerci
kill
vaccin
induc
neglig
vn
antibodi
respons
bassaganyariera
et
al
vanhe
et
al
studi
demonstr
possibl
elicit
increas
vn
titer
kill
prrsv
vaccin
inactiv
viru
use
uv
binari
ethylenimin
coadminist
vaccin
potent
adjuv
vanhe
et
al
studi
amount
inactiv
prrsv
vaccin
dose
tcid
vanhe
et
al
studi
vaccin
dose
approxim
tcid
uvtreat
viru
suggest
plga
nanoparticlebas
intranas
deliveri
kill
prrsv
vaccin
need
significantli
reduc
viru
amount
elicit
antiprrsv
immun
respons
recent
shown
plga
nanoparticlebas
tumor
antigen
fig
analysi
prrsv
specif
recal
cytokin
respons
indic
mononuclear
cell
restimul
harvest
cultur
supernat
analyz
cytokin
elisa
ad
ifng
eh
j
k
l
tgfb
cytokin
secret
immun
cell
cultur
absenc
prrsv
antigen
subtract
test
valu
bar
graph
repres
geometr
mean
cytokin
amount
three
pig
ae
sem
alphabet
b
c
repres
statist
signific
differ
p
unvaccin
vs
kag
unvaccin
vs
nanokag
kag
vs
nanokag
pig
respect
peptid
vaccin
deliveri
could
reduc
requir
vaccin
dose
time
et
al
indic
deliveri
system
potenti
significantli
reduc
requir
amount
kill
prrsv
antigen
dose
prrsv
vn
antibodi
serum
shown
import
viral
clearanc
lopez
et
al
lopez
osorio
osorio
et
al
need
investig
due
lack
complet
viru
clearanc
even
presenc
vn
antibodi
pig
diaz
et
al
michael
murtaugh
person
commun
although
porcin
lung
ig
primarili
igg
gener
protect
iga
respons
essenti
reduc
entri
pathogen
whose
principl
port
entri
mucos
surfac
mcghee
et
al
mucos
immun
elicit
product
iga
antibodi
ogra
karzon
iga
antibodi
protect
clear
viru
infect
viru
neutral
activ
liew
et
al
lack
convinc
studi
role
lung
iga
prrsv
clearanc
infect
vaccin
pig
studi
level
prrsv
specif
iga
antibodi
lung
nanokag
kag
vaccin
pig
found
high
compar
signific
increas
lung
vn
titer
detect
nanokag
receiv
pig
nanokag
immun
pig
increas
level
ifng
respons
observ
lung
blood
serum
pig
unvaccin
vaccin
kag
viru
challeng
detect
vn
titer
absent
nanokag
vaccin
induc
low
level
vn
titer
serum
might
due
nonspecif
effect
low
titer
boost
upon
viral
challeng
suggest
need
potent
adjuv
andor
booster
dose
nanokag
vaccin
induc
high
prr
vn
titer
serum
analysi
lymphoid
tissu
lung
necessari
confirm
effect
nanokag
vaccin
viral
clearanc
challeng
anim
nanoparticl
prepar
plga
contain
hepat
b
rotaviru
influenza
parainfluenza
virus
deliv
mucos
site
mice
gener
protect
immun
respons
thoma
et
al
biodegrad
biocompat
plga
nanoparticl
free
toxic
safe
use
approv
us
food
drug
administr
duncan
studi
plga
nanoparticl
induc
toxic
symptom
vaccin
pig
due
particul
natur
nanoparticl
inher
abil
profession
antigen
present
cell
apc
passiv
phagocytoz
particul
antigen
inaba
et
al
nanoparticlebas
deliveri
vaccin
mucos
site
advantag
note
abund
popul
apc
present
mucos
tissu
lymphoid
organ
bal
fluid
mice
human
pig
greater
cell
macrophag
suggest
intranas
administ
nanokag
probabl
phagocytoz
alveolar
macrophag
earlier
studi
kill
influenza
viru
vaccin
entrap
nanoparticl
administ
adjuv
intranas
mice
rabbit
pig
elicit
protect
immun
respons
respons
induc
pig
significantli
better
intramuscular
vaccin
singh
et
al
therefor
innov
nanotechnolog
base
intranas
vaccin
deliveri
attract
altern
approach
deliv
kill
prrsv
vaccin
pig
insuffici
antiprrsv
immun
vaccin
prrsvinfect
pig
also
link
low
level
ifng
product
suradhat
et
al
enhanc
ifng
respons
antigen
specif
tcell
respons
cell
import
antiprrsv
immun
xiao
et
al
detect
signific
increas
ifng
level
cell
popul
lung
blood
nanokag
vaccin
pig
pig
lymphocyt
subset
phenotyp
abund
possess
memori
thelper
cytolyt
properti
zuckermann
nanokag
immun
pig
signific
increas
cell
frequenc
lung
blood
pig
infect
european
strain
prrsv
neg
correl
frequenc
cell
viremia
report
suggest
protect
role
cell
prrsv
immun
gomezlaguna
et
al
recal
cytokin
respons
lmnc
pbmc
bal
tblnmnc
nanokag
immun
pig
reveal
secret
significantli
increas
cytokin
cytokin
play
import
role
host
defens
viral
infect
induc
ifng
product
nk
cell
also
help
differenti
cell
phenotyp
kaplan
et
al
coadministr
prrsmlv
enhanc
frequenc
ifng
secret
cell
foss
et
al
enhanc
secret
cytokin
associ
protect
cellmedi
immun
respons
mice
deliv
intranas
plgabas
hepat
b
viru
vaccin
immun
cell
three
pig
ae
sem
alphabet
b
c
repres
statist
signific
differ
p
unvaccin
vs
kag
unvaccin
vs
nanokag
kag
vs
nanokag
pig
respect
jaganathan
vya
addit
also
observ
significantli
increas
myeloid
dendrit
cell
rich
popul
lmnc
pbmc
nanokag
compar
kag
vaccin
pig
unlik
nonlymphoid
tissu
lung
contain
larg
fraction
effector
central
memori
lymphocyt
anderson
et
al
unsoeld
pircher
fact
even
lymphocyt
present
perfus
lung
cose
et
al
sinc
includ
lmnc
analyz
phenotyp
analysi
immun
cell
studi
repres
mucos
immun
respons
pig
lung
prrsv
signific
reduct
immunosuppress
cytokin
tgfb
lung
homogen
nanokag
immun
pig
associ
enhanc
ifng
product
pig
cytokin
inhibit
ifng
product
cell
water
et
al
immunosuppress
function
reduc
ifng
product
report
prrsv
infect
pig
charerntantanakul
et
al
earlier
studi
other
barb
et
al
us
renukaradhya
et
al
confirm
pig
lung
homogen
provid
reproduc
compar
data
obtain
bal
fluid
unlik
lung
homogen
method
collect
dilut
factor
bal
fluid
may
significantli
alter
data
lab
lab
thu
lung
homogen
may
suitabl
sampl
lung
immun
analysi
minim
variat
point
due
absenc
data
bal
fluid
could
conclud
sampl
better
prrsv
vaccin
andor
challeng
anim
infiltr
treg
infect
pig
lung
microenviron
contribut
secret
high
level
tgfb
didierlaur
et
al
increas
frequenc
treg
prrsv
infect
pig
report
silvacampa
et
al
nanokag
kag
vaccin
pig
reduct
treg
popul
lmnc
pbmc
tbln
observ
signifi
vaccin
strategi
dampen
treg
respons
favor
prrsv
specif
respons
perform
immun
cell
analys
singl
time
point
data
although
support
viral
clearanc
consid
natur
macrophag
neutrophil
lymphocyt
traffick
recruit
difficult
precis
document
direct
correl
immun
cell
phenotyp
data
observ
respons
pig
possess
rel
larg
popul
gd
cell
compar
speci
consid
import
innat
immun
cell
mucos
site
olin
et
al
nanokag
vaccin
pig
increas
frequenc
gd
cell
lung
blood
tbln
suggest
possibl
protect
role
play
gd
cell
prrsv
immun
conclus
studi
first
time
demonstr
efficaci
plga
nanoparticleencapsul
prrsv
kill
vaccin
induc
antiprrsv
specif
humor
cellmedi
immun
respons
concertedli
contribut
better
clearanc
viremia
compar
control
kill
vaccin
studi
requir
evalu
antiprrsv
crossprotect
immun
vaccin
pig
summari
intranas
deliveri
nanokag
vaccin
promis
need
investig
improv
